Cytokinetics Inc (NASDAQ: CYTK) has reported a loss for its first fiscal quarter (ending March 31) of $-1.33 versus a loss $-1.38 for the same period a year ago. This result fell short of the consensus estimate of $-1.20 by $-0.13. For the latest four quarters through March 31, E.P.S. were $-5.40 versus $-4.58 for the same period a year ago.
Recent Price Action
Cytokinetics Inc (NASDAQ: CYTK) stock declined slightly by -0.02% on 5/8/24. The stock closed at $65.27. However, trading volume in this decline was exceptionally low at 42% of normal. The stock has been exceptionally strong relative to the market over the last nine months and has risen 6.4% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be below the cost of capital, CYTK is expected to be a major Value Eraser.
Cytokinetics is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment